Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. entered into Asset Purchase and Settlement Agreement with Commave Therapeutics SA valued at $50.0 million (effective 2026-03-13).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Commave Therapeutics SA
- Value
- $50.0 million
- Effective
- 2026-03-13
Exact text from the filing
On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Collaboration and License Agreement between the parties dated September 3, 2019, as amended (the “AZSTARYS License Agreement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. terminated Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC valued at $63.0 million (effective 2026-03-12).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC
- Value
- $63.0 million
- Effective
- 2026-03-12
Exact text from the filing
On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”).
View on SEC.gov